Picking Up the Pace

PrEP introduction is gaining traction around the world. Check out AVAC’s graphic showing global totals, and the uptick in implementation studies, regulatory approvals, global recommendations and more. 

AIDS Vaccines by the Numbers: Trials, discoveries, money and more

We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.

Trans Inclusion: Charting HIV Research into the Future: A Manifesto and Scorecard for Advocates and Researchers

Thursday, January 26, 2023


During this webinar, panelists unpacked the No Data No More manifesto and discussed preliminary findings from the TG scorecard, which looked at transgender representation in clinical trials over time. Speaker details, recording, and resources below.

Featured Leigh Ann van der Merwe — Founder and Director: Social, Health & Empowerment Feminist Collective of Transgender Women of Africa; Brian Minalga — AVAC consultant, Trans Inclusion Initiative; and Cindra Feuer — AVAC Senior Program Manager: Partnerships & Capacity Strengthening


Recording / Slides / Resources

Re: Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection

AVAC submits comment and response to the United States Preventative Services Task Force (USPSTF) Draft Recommendation statement for PrEP. The USPSTF recommended an “A” Grade for PrEP that includes CAB for PrEP.

HIV Vaccines: An introductory factsheet

This is an updated introductory two-page document that describes HIV vaccines research and reviews key developments in the field.

Participant Application Form

Download the application here or click the link to the right of this page. Please note, you will need to download and fill the application on a laptop or desktop computer. It is not possible to use a mobile phone to fill out the application.

The Advocacy Navigator is an AVAC initiative combining training and mentorship to young and emerging advocates in the field of HIV prevention advocacy. The program involves three months of coursework and project development, followed by three months of “implementation” whereby Navigators implement all or a portion of their Community Advocacy Project plan with the support of their mentor. More information at www.avac.org/navigator.

Biomedical HIV Prevention Research in 2022 and Beyond

This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.

Correlations between Oral Pre-Exposure Prophylaxis (PrEP) Initiations and Policies that Enable the Use of PrEP to Address HIV Globally

This article from PLoS Global Public Health presents the results of an analysis examining whether policies enabling broad PrEP eligibility, HIV self-testing, and lowered age of consent to HIV testing and treatment services are correlated with PrEP uptake.

Celebrating the Role of Communities: A focus on choice in HIV prevention

Presentation given by Rosemary Mburu, Executive Director of WACI Health, on World AIDS Day 2022 describing her organization and providing a short overview of the field.

New Products Are Needed But a New Paradigm is Essential

With all the talk about new HIV prevention products such as the dapivirine vaginal ring or injectable cabotegravir for PrEP (CAB for PrEP), what’s little understood is how to match proven products with the programs, policies and political will needed to get them to the people who need them. This episode explores the shifting landscape in HIV prevention and how this moment gives the world a chance to finally reimagine how to DELIVER prevention.

We go from big picture to grass roots, and dig into what it’s going to take to reach global targets. There’s a new road map out from the Global HIV Prevention Coalition with a big vision and a new target of less than 370,000 new infections by 2025. And PEPFAR’s new Strategic Direction talks about a target for ending the epidemic as a public health threat by 2030, but how are we going to get there?

This episode brings three perspectives together:

PEPFAR Ambassador Dr. John Nkengasong describes a model to scale up prevention in 5 countries and show impact in 1-2 years.

Executive Director of HEPS-Uganda, and former AVAC Advocacy Fellow, Kenneth Mwehonge talks about the commitments needed from a range of stakeholders to bring the Coalition’s new roadmap to life, and hit 2030 targets.

Lilian Benjamin Mwakyosi, the Executive Director of DARE and former AVAC Advocacy Fellow, talks about the day-to-day obstacles faced by young women who need prevention, what’s working now and what needs to change in HIV prevention programs.

Highlights

  • Listen to the ambassador’s appeal for an aggressive strategy to scale up combination prevention, including injectable cabotegravir for PrEP.

Resources